Theriva Biologics
TOVX
56 hedge funds and large institutions have $75.5M invested in Theriva Biologics in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 6 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 5
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
10% more funds holding
Funds holding: 51 → 56 (+5)
6% more capital invested
Capital invested by funds: $71.6M → $75.5M (+$3.98M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$601K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
+$481K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$391K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$316K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$225K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$801K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$362K |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
-$298K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$150K |
| 5 |
BCM
Bluefin Capital Management
New York
|
-$105K |
TOVX Hedge Fund Activity: Q1 2016 in Review
56 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2016, worth a combined $75.5M — up 5.6% from $71.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TOVX positions and 6 closed out — a net gain of 5 holders — while 16 added to existing stakes and 5 trimmed.
The largest buyer was Bridgeway Capital Management, adding an estimated $601K. The largest seller was Belmont Global Advisors, exiting entirely with an estimated $801K sold.
- 56 institutional investors held Theriva Biologics (TOVX) as of Q1 2016, up from 51 in Q4 2015.
- Funds reported $75.5M of Theriva Biologics stock for Q1 2016, up 5.6% quarter-over-quarter.
- 11 funds opened new Theriva Biologics positions in Q1 2016 and 6 closed out, a net change of +5 holders.
- The largest Theriva Biologics buyer in Q1 2016 was Bridgeway Capital Management, an estimated $601K added.
- The largest Theriva Biologics seller in Q1 2016 was Belmont Global Advisors, an estimated $801K sold.
Based on aggregated 13F filings for Q1 2016.